Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Interferon-alpha in chronic myeloid leukemia]

R Hehlmann1

  • 1III, Medizinischen Universitätsklinik, Klinikum Mannheim, Universität Heidelberg.

Fortschritte Der Medizin
|March 30, 1997
PubMed
Summary

The standard treatment for chronic myeloid leukemia (CML) combines interferon alpha and hydroxyurea, prolonging survival. Early intervention and specialized CML centers are crucial for optimal patient outcomes.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia.

Leukemia·2020
Same author

Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML.

Leukemia·2018
Same author

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants.

Leukemia·2017
Same author

Expression of the CTLA-4 ligand CD86 on plasmacytoid dendritic cells (pDC) predicts risk of disease recurrence after treatment discontinuation in CML.

Leukemia·2017
Same author

Which patients with myelofibrosis should receive ruxolitinib therapy? ELN-SIE evidence-based recommendations.

Leukemia·2016
Same author

Prof. Thomas Büchner (22 September 1934-5 August 2016)-A leading European hematologist and AML trialist.

Leukemia·2016

Area of Science:

  • Hematology
  • Oncology
  • Pharmacology

Context:

  • Chronic myeloid leukemia (CML) management.
  • Current standard treatment involves interferon alpha and hydroxyurea.
  • Limited survival benefits with current non-curative therapies.

Purpose:

  • To outline the current standard of care for CML.
  • To highlight the importance of early treatment initiation.
  • To discuss alternative and curative treatment options.

Summary:

  • Interferon alpha and hydroxyurea combination therapy is the current standard for chronic phase CML, offering a median survival of approximately five years.
  • Early initiation of interferon alpha treatment is critical for maximizing survival benefits.
  • Allogeneic bone marrow transplantation remains the only curative option; autotransplantation with interferon alpha maintenance is an alternative when donors are unavailable.

Impact:

  • Emphasizes the need for timely diagnosis and referral to specialized CML treatment centers.
  • Highlights the limitations of current non-curative therapies and the importance of curative options.
  • Informs clinical practice regarding optimal CML management strategies.

Related Experiment Videos